


PHOE-0057



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
JAN 29 2002  
TECH CENTER 1600/2900

In re application of:

Clark

Serial No.: 09/504,380<sup>280</sup>

Group Art Unit: 1647


Filed: February 15, 2000

Examiner: D. Romeo

For: MODIFIED TUMOR NECROSIS FACTOR

I, Gwilym J.O. Attwell, Registration No. 45,449 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On November 20, 2001

  
Gwilym J.O. Attwell, Reg. No. 45,449

Assistant Commissioner for  
Patents  
Washington, D.C. 20231

Dear Sir:

RECEIVED  
JAN 14 2002  
TECH CENTER 1600/2900

RESPONSE

This amendment is being filed in response to the communication from the Patent Office dated October 23, 2001, which contained a "Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures."

Please amend the application as follows.